Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2012

View Archived Issues

Fifth phase III study of QVA-149 meets primary endpoint

New Afinitor formulation approved in U.S.

Creabilis products show promise as topical analgesics

PAR1 receptor antagonist prevents heart failure-induced atrial remodeling

Topical cream improves female sexual arousal disorder in phase III trial

Research at Kyowa Hakko Kirin produces new calcium channel antagonists

Merck KGaA patents novel protein kinase inhibitors

Novel inhibitors of JAK3 presented

New heat shock protein inhibitors designed in Japan

Lead product for Parkinson's disease advances through preclinical studies

Zinc peptidase implicated in ACS pathogenesis

Humira indication broadened in Europe

Enrollment complete in phase Ib trial of CALAA-01

ARIAD submits MAA to EMA

PharmaMar product gets orphan drug designation

Exelixis provides update on FDA meeting for cabozantinib

Infradure tissue implant cleared for two hepatitis C trials in Israel

Genmab and Janssen Biotech form worldwide agreement

New drug approved for IBS-C and CIC

Sunovion signs definitive acquisition agreement

FDA grants orphan drug designation to ARLN-05

Lead Nordic Nanovector product clear to enter clinic

Bayer HealthCare submits NDA for regorafenib

New genetic test predicts response to antipsychotics/antidepressants

PR-610 enters phase I/II study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...